325 related articles for article (PubMed ID: 37545384)
1. Clinico-histological and molecular features of hepatocellular carcinoma from nonalcoholic fatty liver disease.
Fujiwara N; Nakagawa H
Cancer Sci; 2023 Oct; 114(10):3825-3833. PubMed ID: 37545384
[TBL] [Abstract][Full Text] [Related]
2. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
[TBL] [Abstract][Full Text] [Related]
3. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
5. Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.
Vachliotis ID; Valsamidis I; Polyzos SA
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958479
[TBL] [Abstract][Full Text] [Related]
6. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
7. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.
Ando S; Shibahara J; Hayashi A; Fukayama M
Virchows Arch; 2015 Nov; 467(5):535-42. PubMed ID: 26311355
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows.
Costante F; Airola C; Santopaolo F; Gasbarrini A; Pompili M; Ponziani FR
World J Gastrointest Oncol; 2022 Sep; 14(9):1622-1636. PubMed ID: 36187401
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
10. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study.
Yeh MM; Liu Y; Torbenson M
Hum Pathol; 2015 Nov; 46(11):1769-75. PubMed ID: 26410018
[TBL] [Abstract][Full Text] [Related]
11. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
Chen J; Song S; Li X; Bian D; Wu X
Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways.
Perumpail RB; Liu A; Wong RJ; Ahmed A; Harrison SA
World J Hepatol; 2015 Oct; 7(22):2384-8. PubMed ID: 26464753
[TBL] [Abstract][Full Text] [Related]
13. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.
Khan FZ; Perumpail RB; Wong RJ; Ahmed A
World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.
Ahmad MI; Khan MU; Kodali S; Shetty A; Bell SM; Victor D
J Hepatocell Carcinoma; 2022; 9():477-496. PubMed ID: 35673598
[TBL] [Abstract][Full Text] [Related]
16. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y; Wang W; Morgan MP; Robson T; Annett S
Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma.
Alqahtani SA; Chan WK; Yu ML
Clin Liver Dis; 2023 May; 27(2):211-223. PubMed ID: 37024203
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.
Lin BZ; Lin TJ; Lin CL; Liao LY; Chang TA; Lu BJ; Chen KY
J Chin Med Assoc; 2021 Jun; 84(6):606-613. PubMed ID: 33871391
[TBL] [Abstract][Full Text] [Related]
19. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
Loomba R; Lim JK; Patton H; El-Serag HB
Gastroenterology; 2020 May; 158(6):1822-1830. PubMed ID: 32006545
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
Wong CR; Nguyen MH; Lim JK
World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
